Healthcare / Elderly CareUS
← Sticker Wall
JOURNEY · DETAIL
Neuralink: From Sci-Fi to First Human Implants, Musk Bets on the Trillion-Dollar Track
Founded: Elon Musk · Neuralink Corp.
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionUS
ScaleMid-size
ChannelB2B
Origin
Long concerned that AI poses an existential threat to humanity, Musk believes humans must enhance cognitive abilities through brain-computer interfaces to symbiotically coexist with AI. In 2016, he co-founded Neuralink with several neuroscientists in California, aiming to develop high-bandwidth, low-trauma brain implant devices to achieve seamless integration between the human brain and the digital world. The early team originated from institutions like the University of California, San Francisco, attempting to overcome the traditional invasive bottlenecks of brain-computer interfaces using flexible electrodes and robotic surgery.
Milestones
2016
Founded Turning Point
In 2016, Musk secretly incorporated Neuralink in California, with initial funding of about $150 million coming from himself and early investors. The team initially consisted of about 10 engineers focused on developing implantable flexible electrode threads, aiming to implant thousands of electrode channels into the brain—far surpassing any contemporary product. In 2017, the company first disclosed its flexible electrode technology in a paper published in Neuralink, sparking scientific interest.
2019
Animal Testing Failure
In 2019, Neuralink conducted electrode implantation tests on live pigs and rhesus macaques. However, a 2020 public demonstration showing an implanted monkey playing video games sparked animal ethics controversies. The USDA investigated allegations of monkey mistreatment, confirming violations and issuing fines in 2022. Additionally, the deaths of multiple test monkeys led the FDA to reject its human clinical trial application in 2022, requesting more safety data.
2023
FDA Approval Turning Point
In May 2023, the FDA approved Neuralink to initiate its first human clinical trial, allowing a 6-year feasibility study. Prior to this, the company had accumulated extensive animal data and passed third-party audits. Upon approval, Neuralink opened patient recruitment for volunteers with severe neurological injuries such as quadriplegia. The device features 1,024 electrode channels, with implantation planned to be completed within 15 minutes by the R1 surgical robot.
2024
First Human Implant PMF
Musk announced via the X platform that the world's first human implant had been completed. The patient, 29-year-old quadriplegic Noland Arbaugh, was able to control a computer mouse to play games using his thoughts 24 hours post-surgery, recovering partial autonomous control capabilities. However, weeks after surgery, some electrode threads retracted from brain tissue, impairing device functionality. Neuralink maintained basic functionality through software algorithm adjustments, exposing significant flaws in material stability.
2025
Scaling Expansion Growth
By the end of 2025, Neuralink had completed over 20 human implants, reaching a valuation of $9.0 billion. In August 2025, the company completed a new financing round, with Reuters reporting approximately $430 million injected. That same year, an updated version of the N1 was released, optimizing electrode thread coatings and encapsulation to reduce inflammatory responses, alongside the introduction of a Bluetooth-connected wireless charger. In December 2025, the company announced plans for mass production in 2026, targeting thousands of units annually.
2026
Mass Production Launch Turning Point
On March 18, 2026, Neuralink held a launch event showcasing a new-generation surgical robot capable of automatically performing craniotomies, implantations, and sutures, reducing single implantation times from about 2 hours to 1.5 seconds (referring to the electrode insertion action). The company claimed over 30,000 people had signed up for implants, though the FDA has only approved about 12 clinical centers, limiting actual operational capacity. The event also released a 23-month follow-up report on the first long-term subject, Arbaugh, showing he could independently use cursors and wheelchair control systems, while noting that the initially unstable electrode threads had recovered 85% of their functionality.
Turning Points
- After the FDA rejected the clinical application in 2022, Neuralink completely restructured its animal testing compliance system and transparentized test data, ultimately earning conditional approval in 2023.
- The electrode thread retraction observed in the first subject, Arbaugh, forced the team to shift toward softer titanium nitride coatings and tighter electrode spacing; this improvement was directly applied to all subsequent implants.
- The introduction of automated surgical robots for batch deployment in 2025 lowered the cost per surgery from about $1 million to roughly $300,000, paving the way for commercialization.
Failures & Pitfalls
- The 2020 public macaque demonstration provoked protests from animal rights organizations, and reports of monkeys dying from surgical complications triggered a public trust crisis.
- The 2022 FDA rejection of human clinical applications was based on insufficient long-term electrode stability data and flaws in sterilization processes.
- Weeks after the first human implant, approximately 15% of the electrode threads detached from the cortex, causing signal degradation and forcing reliance on algorithmic compensation.
- Multiple complaints from subjects regarding device charging heat in 2024 led the FDA to mandate temperature sensors and restrict maximum charging power.
关键成功要素
- Created micron-level flexible electrode threads with a 1,024-channel density over 10 times higher than contemporary competitors, resolving inflammatory issues associated with traditional rigid electrodes.
- Independently developed the R1 surgical robot, utilizing 5-axis linkage and optical navigation to elevate implantation precision from millimeter to sub-millimeter scales.
- Adopted a closed-loop organizational transparency strategy, releasing animal and human data in batches to gradually appease regulators and the public.
- Expanded brain-computer interfaces to indications such as paralysis, ALS, and depression, creating a versatile multi-indication platform.
Lessons
- The clinical approval cycle for biomedical products far exceeds software company expectations, requiring at least a 5-year compliance buffer.
- Early over-promotion and technology demos amplify the risk of failure; both the monkey incident and electrode detachment stemmed from overly high public expectations.
- Hardware device failures cannot be fully predicted, necessitating software-based compensation mechanisms and redundant electrode channels.
- The core of mass production lies in the standardization of surgical robots rather than the implants themselves, as automation reduces dependence on surgeon skill.
Core Data
- 估值：$9.0 billion (End of 2025) (Based on public disclosures, independent verification pending)
- 累计人体植入数：Over 20 cases (Based on public disclosures, independent verification pending)
- 首例受试者随访月数：23 months (Based on public disclosures, independent verification pending)
- 单次手术电极植入时间秒：1.5 seconds (Claimed at 2026 launch event) (Based on public disclosures, independent verification pending)
- 报名等待植入人数：Over 30,000 people (March 2026) (Based on public disclosures, independent verification pending)
- 已获FDA批准临床中心数：Approximately 12 centers (2026) (Based on public disclosures, independent verification pending)
- 2025年融资额：$430 million (As reported by Reuters) (Based on public disclosures, independent verification pending)
Competitors / Peers
The brain-computer interface sector has heated up rapidly in recent years. Synchron bypassed craniotomy using endovascular micro-stent electrodes, earning FDA approval as early as 2021 and raising over $300 million in cumulative funding by 2025. Precision Neuroscience focuses on minimally invasive film electrodes and completed human trials in 2024, while Blackrock Neurotech follows the traditional invasive route with multiple long-term subjects. Additionally, tech giants like Meta and Alphabet are laying groundwork in non-invasive devices. Neuralink's differentiation lies in its high channel count, automated surgical robots, and Musk's personal brand power. However, regulatory approvals, long-term safety, and pricing models remain common hurdles for all players, putting the industry as a whole in a transitional phase from laboratory validation to scaled application in 2026.